Sign In

Login

Password

Forgot Password ? Sign Up

Pralsetinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pralsetinib" in English language version.

refsWebsite
Global rank English rank
13web.archive.org
1st place
1st place
5tga.gov.au
3,984th place
2,622nd place
4nih.gov
4th place
4th place
3fda.gov
447th place
338th place
3europa.eu
68th place
117th place
2doi.org
2nd place
2nd place
1hres.ca
low place
low place
1prnewswire.com
406th place
258th place
1roche.com
low place
low place
1semanticscholar.org
11th place
8th place

doi.org

europa.eu

ema.europa.eu

  • "Gavreto EPAR". European Medicines Agency (EMA). 14 September 2021. Archived from the original on 10 December 2021. Retrieved 9 December 2021.
  • "Gavreto: Pending EC decision". European Medicines Agency. 17 September 2021. Archived from the original on 17 September 2021. Retrieved 17 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

fda.gov

hres.ca

hpr-rps.hres.ca

nih.gov

pubmed.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

ncbi.nlm.nih.gov

prnewswire.com

roche.com

semanticscholar.org

api.semanticscholar.org

tga.gov.au

  • "Gavreto". Therapeutic Goods Administration (TGA). 6 April 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
  • "Gavreto pralsetinib 100 mg hard capsule bottle (380812)". Therapeutic Goods Administration (TGA). 30 March 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
  • "Gavreto (Roche Products Pty Ltd)". Therapeutic Goods Administration (TGA). 26 April 2023. Retrieved 28 April 2023.
  • "Gavreto (Roche Products Pty Ltd)". Therapeutic Goods Administration (TGA). 26 April 2023. Retrieved 28 April 2023.
  • "AusPAR: Gavreto | Therapeutic Goods Administration (TGA)". Archived from the original on 31 March 2024. Retrieved 5 April 2025.

web.archive.org

  • "Gavreto". Therapeutic Goods Administration (TGA). 6 April 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
  • "Gavreto pralsetinib 100 mg hard capsule bottle (380812)". Therapeutic Goods Administration (TGA). 30 March 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
  • "AusPAR: Gavreto | Therapeutic Goods Administration (TGA)". Archived from the original on 31 March 2024. Retrieved 5 April 2025.
  • "Summary Basis of Decision (SBD) for Gavreto". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  • "Gavreto- pralsetinib capsule". DailyMed. 9 September 2020. Archived from the original on 28 November 2020. Retrieved 24 September 2020.
  • "Gavreto EPAR". European Medicines Agency (EMA). 14 September 2021. Archived from the original on 10 December 2021. Retrieved 9 December 2021.
  • "Gavreto Product information". Union Register of medicinal products. Archived from the original on 5 March 2023. Retrieved 3 March 2023.
  • "FDA approves pralsetinib for RET-altered thyroid cancers". Center for Drug Evaluation and Research. U.S. Food and Drug Administration. 11 June 2021. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
  • "FDA approves pralsetinib for lung cancer with RET gene fusions". U.S. Food and Drug Administration (FDA). 4 September 2020. Archived from the original on 9 September 2020. Retrieved 8 September 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  • "Blueprint Medicines Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" (Press release). Blueprint Medicines. 4 September 2020. Archived from the original on 9 September 2020. Retrieved 8 September 2020 – via PR Newswire.
  • "Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer". Roche (Press release). 7 September 2020. Archived from the original on 9 September 2020. Retrieved 8 September 2020.
  • "Drug Trial Snapshot: Gavreto". U.S. Food and Drug Administration. 4 September 2020. Archived from the original on 25 October 2020. Retrieved 16 September 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  • "Gavreto: Pending EC decision". European Medicines Agency. 17 September 2021. Archived from the original on 17 September 2021. Retrieved 17 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.